Literature DB >> 22890931

Evaluation of circulating endothelial precursor cells in cancer patients.

Francesco Bertolini1, Patrizia Mancuso, Liat Benayoun, Svetlana Gingis-Velitski, Yuval Shaked.   

Abstract

Results obtained from preclinical studies have shown that endothelial progenitor cells (EPCs) play a crucial role in tumor growth and metastasis. In the clinic, EPCs are present in the peripheral blood of cancer patients in higher numbers than in healthy subjects. These cells are mobilized from the bone marrow compartment to the periphery in response to certain cytokines and growth factors. Growing body of evidence suggests that following acute cytotoxic drug therapy levels of circulating EPCs (CEPs) can change significantly in both mouse and human. These changes may predict the efficacy of some anticancer drug treatments. Therefore, the validation and standardization of a procedure to detect CEPs and monitor their kinetic is an important step towards the use of such cells as a possible biomarker to predict clinical outcome. In this chapter, we describe a flow cytometry technique to detect CEPs obtained from human blood specimens stored in both fresh and frozen conditions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22890931     DOI: 10.1007/978-1-61779-943-3_14

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  4 in total

1.  Circulating Tumor Cells: Who is the Killer?

Authors:  Patrizia Paterlini-Bréchot
Journal:  Cancer Microenviron       Date:  2014-12-20

2.  The synergistic effect of everolimus and chloroquine on endothelial cell number reduction is paralleled by increased apoptosis and reduced autophagy occurrence.

Authors:  Anna Grimaldi; Maria Luisa Balestrieri; Nunzia D'Onofrio; Gilda Di Domenico; Cosimo Nocera; Monica Lamberti; Giuseppe Tonini; Alice Zoccoli; Daniele Santini; Michele Caraglia; Francesco Pantano
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

3.  Bevacizumab specifically decreases elevated levels of circulating KIT+CD11b+ cells and IL-10 in metastatic breast cancer patients.

Authors:  Sarah Cattin; Benoît Fellay; Sylvain Pradervand; Andreas Trojan; Thomas Ruhstaller; Curzio Rüegg; Gregor Fürstenberger
Journal:  Oncotarget       Date:  2016-03-08

Review 4.  Mechanisms of receptor tyrosine kinase activation in cancer.

Authors:  Zhenfang Du; Christine M Lovly
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.